Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Parkinson's Disease

  Free Subscription


18.02.2019

1 Ann Neurol
1 BMC Neurol
1 J Neural Transm (Vienna)
2 Mov Disord
1 Neurobiol Dis
5 Neurology
1 Neurosci Lett
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Neurol

  1. BAKSHI R, Macklin EA, Logan R, Zorlu MM, et al
    Higher urate in LRRK2 mutation carriers resistant to Parkinson's disease.
    Ann Neurol. 2019 Feb 13. doi: 10.1002/ana.25436.
    PubMed     Text format     Abstract available


    BMC Neurol

  2. SILVEIRA CRA, MacKinley J, Coleman K, Li Z, et al
    Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
    BMC Neurol. 2019;19:20.
    PubMed     Text format     Abstract available


    J Neural Transm (Vienna)

  3. ALWARDAT M, Schirinzi T, Di Lazzaro G, Sancesario GM, et al
    Association between physical activity and dementia's risk factors in patients with Parkinson's disease.
    J Neural Transm (Vienna). 2019 Feb 12. pii: 10.1007/s00702-019-01979.
    PubMed     Text format     Abstract available


    Mov Disord

  4. QUATTRONE A, Morelli M, Vescio B, Nigro S, et al
    Refining initial diagnosis of Parkinson's disease after follow-up: A 4-year prospective clinical and magnetic resonance imaging study.
    Mov Disord. 2019 Feb 13. doi: 10.1002/mds.27621.
    PubMed     Text format     Abstract available

  5. DIEDERICH NJ, James Surmeier D, Uchihara T, Grillner S, et al
    Parkinson's disease: Is it a consequence of human brain evolution?
    Mov Disord. 2019 Feb 13. doi: 10.1002/mds.27628.
    PubMed     Text format    


    Neurobiol Dis

  6. MEIDAHL AC, Moll CKE, van Wijk B, Gulberti A, et al
    Synchronised spiking activity underlies phase amplitude coupling in the subthalamic nucleus of Parkinson's disease patients.
    Neurobiol Dis. 2019 Feb 9. pii: S0969-9961(19)30037.
    PubMed     Text format     Abstract available


    Neurology

  7. SCHUEPBACH WMM, Tonder L, Schnitzler A, Krack P, et al
    Quality of life predicts outcome of deep brain stimulation in early Parkinson disease.
    Neurology. 2019 Feb 8. pii: WNL.0000000000007037.
    PubMed     Text format     Abstract available

  8. CHEN CC
    Is outcome of subthalamic nucleus deep brain stimulation in Parkinson disease predictable?
    Neurology. 2019 Feb 8. pii: WNL.0000000000007023.
    PubMed     Text format    

  9. ESPAY AJ, Vizcarra JA, Marsili L, Lang AE, et al
    Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.
    Neurology. 2019;92:329-337.
    PubMed     Text format     Abstract available

  10. RUTTEN S, Vriend C, Smit JH, Berendse HW, et al
    Bright light therapy for depression in Parkinson disease: A randomized controlled trial.
    Neurology. 2019 Feb 15. pii: WNL.0000000000007090.
    PubMed     Text format     Abstract available

  11. VIDENOVIC A, Messinis L
    Enlightened PD: A novel treatment for Parkinson disease?
    Neurology. 2019 Feb 15. pii: WNL.0000000000007078.
    PubMed     Text format    


    Neurosci Lett

  12. WANG X, Shen N, Lu Y, Tan K, et al
    Vitamin D receptor polymorphisms and the susceptibility of Parkinson's disease.
    Neurosci Lett. 2019 Feb 11. pii: S0304-3940(19)30101.
    PubMed     Text format     Abstract available


    PLoS One

  13. CANARIO N, Sousa M, Moreira F, Duarte IC, et al
    Impulsivity across reactive, proactive and cognitive domains in Parkinson's disease on dopaminergic medication: Evidence for multiple domain impairment.
    PLoS One. 2019;14:e0210880.
    PubMed     Text format     Abstract available

  14. WON JH, Kim M, Park BY, Youn J, et al
    Effectiveness of imaging genetics analysis to explain degree of depression in Parkinson's disease.
    PLoS One. 2019;14:e0211699.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: